Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

breakthrough therapy

- PMLiVE

Pfizer and Triana enter molecular glue degrader partnership worth over $1.5bn

The companies will aim to discover new drugs for cancer and other severe diseases

- PMLiVE

Age is not just a number when it comes to clinical trials

In this blog we look at the critical underrepresentation of older adults in clinical trials, emphasising the need for inclusive trial designs and targeted strategies to ensure safe and effective...

Cuttsy + Cuttsy

- PMLiVE

Astellas’ Vyloy approved by FDA as first-line gastric cancer combination treatment

Approximately 26,890 new cases of gastric cancer will be diagnosed in the US this year

- PMLiVE

Innovative Trials named a finalist at the PME Award

Patient recruitment and retention company, Innovative Trials, was shortlisted as a finalist in the PME Award for its collaboration with US non-profit Oliver Patch Project to improve patient outcomes.

Innovative Trials

- PMLiVE

GSK’s investigational antibiotic granted FDA priority review for urinary tract infections

Gepotidacin could be the first in a new class of oral antibiotics for uncomplicated UTIs in over 20 years

- PMLiVE

Sanofi and Orano Med partner to advance radioligand therapies for rare cancers

The companies will invest in a new entity that will operate under the Orano Med brand

- PMLiVE

Pfizer’s Hympavzi granted FDA approval to treat haemophilia in adult and paediatric patients

More than 800,000 people globally are affected by the genetic blood disorder

- PMLiVE

FDA advisory committee recommends Stealth’s elamipretide for Barth syndrome

The ultra-rare genetic disease affects approximately 150 people in the US

- PMLiVE

TOMORROW: Last chance to register for FREE Origins Webinar: How Patient Involvement is Transforming Clinical Trials – Reserve Your Spot Today!

Last chance to register for our exclusive webinar, “Why Patient Perspectives Matter: Driving Success in Clinical Trials”!   Wendy Erler and Alfred Samuels are ready to join Su Smith and...

Origins – The Patient Focused Specialists

- PMLiVE

Pfizer shares positive phase 3 results for Talzenna combination in prostate cancer

Up to 20% of patients will develop metastatic castration-resistant disease within five to seven years of diagnosis

- PMLiVE

Roche’s Itovebi combination granted FDA approval for advanced breast cancer

Approximately 310,720 women will be diagnosed with invasive breast cancer in the US this year

- PMLiVE

Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval

About 614,000 people are diagnosed with bladder cancer globally every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links